Efficient lightweight CNN for automated classification of B-cell acute lymphoblastic leukemia.

Comput Biol Chem

Department of Information Technology, Technical College of Informatics, Akre University for Applied Sciences, Akre, Kurdistan Region, Iraq. Electronic address:

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematological malignancy that primarily affects children but can also occur in adults, progressing rapidly and requiring urgent clinical intervention. Late-stage diagnosis often results in reduced survival rates and typically depends on costly, time-intensive diagnostic procedures. Peripheral blood smear (PBS) imaging plays a central role in the preliminary screening of B-ALL and provides an accessible foundation for computer-assisted diagnosis. To support early and efficient classification, this study proposes a lightweight convolutional neural network (CNN) designed to classify B-ALL subtypes directly from PBS images without the need for pre-segmentation. The model is computationally efficient, comprising only 986,126 trainable parameters, and integrates Squeeze-and-Excitation (SE) modules within Inverted Residual Blocks to strengthen feature representation. Experimental results demonstrated excellent classification performance, achieving 100 % accuracy, precision, sensitivity, specificity, F1-score, and Matthews correlation coefficient (MCC). To further assess generalizability, cross-dataset validation was performed on the independent Blood Cells Cancer (ALL) dataset without retraining or fine-tuning, yielding a robust accuracy of 99.85 %. Model interpretability was performed using Gradient-weighted Class Activation Mapping (Grad-CAM) and Local Interpretable Model-agnostic Explanations (LIME), which provided visual explanations and highlighted key discriminative cellular features, respectively. Taken together, these results demonstrate that the proposed framework delivers a highly accurate, resource-efficient, and interpretable solution for B-ALL classification, underscoring its strong potential for integration into real-world clinical practice. Additionally, the implementation code for this study is publicly available at: https://github.com/awazabbas/Efficient-Lightweight-CNN-for-Automated-Classification-of-B-cell-Acute-Lymphoblastic-Leukemia-.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiolchem.2025.108645DOI Listing

Publication Analysis

Top Keywords

b-cell acute
8
acute lymphoblastic
8
lymphoblastic leukemia
8
efficient lightweight
4
lightweight cnn
4
cnn automated
4
classification
4
automated classification
4
classification b-cell
4
leukemia b-cell
4

Similar Publications

Acute lymphoblastic leukemia (ALL) preferentially localizes in the bone marrow (BM) and displays recurrent patterns of medullary and extra-medullary involvement. Leukemic cells exploit their niche for propagation and survive selective pressure by chemotherapy in the BM microenvironment, suggesting the existence of protective mechanisms. Here, we established a three-dimensional (3D) BM mimic with human mesenchymal stromal cells and endothelial cells that resemble vasculature-like structures to explore the interdependence of leukemic cells with their microenvironment.

View Article and Find Full Text PDF

Objective: To develop a novel prognostic scoring system for severe cytokine release syndrome (CRS) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 chimeric antigen receptor (CAR)-T-cell therapy, aiming to optimize risk mitigation strategies and improve clinical management.

Methods: This single-center retrospective cohort study included 125 B-ALL patients who received anti-CD19 CAR-T-cell therapy from January 2017 to October 2023. These cases were selected from a cohort of over 500 treated patients on the basis of the availability of comprehensive baseline data, documented CRS grading, and at least 3 months of follow-up.

View Article and Find Full Text PDF

Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.

View Article and Find Full Text PDF

The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden.

Am J Hematol

September 2025

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.

Blinatumomab is approved for the treatment of relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Studies have correlated pre-blinatumomab high disease burden (HDB) [> 50% bone marrow blasts (BMB)] with lower response rates and increased risk for toxicities, including cytokine release syndrome (CRS) and neurotoxicity (NT). While the administration of pre-blinatumomab cytoreductive therapy is an appealing approach, larger studies validating the beneficial effect of this strategy in patients with HDB are lacking.

View Article and Find Full Text PDF

We report 35 patients who had a leukemic phase of diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements, also known as double-hit lymphoma (DHL). There were 23 men and 12 women with a median age of 57 years (range, 29-82). Eight patients had an established DHL diagnosis and later developed a leukemic phase of disease and 27 presented with DHL and a leukemic phase of disease at initial diagnosis.

View Article and Find Full Text PDF